

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

RPP decision paper

Review of TA231; Agomelatine for the treatment of major depressive episodes

Final recommendation post consultation

The forthcoming clinical guideline on depression in adults should make recommendations on the use of agomelatine, meaning that the termination advice in TA231 would be withdrawn at the point which the clinical guideline is published.

1. Background

This termination advice was issued in July 2011.

2. Proposal put to consultees and commentators

The forthcoming clinical guideline on depression in adults should make recommendations on the use of agomelatine, meaning that the termination advice in TA231 would be withdrawn at the point which the clinical guideline is published.

3. Summary of consultee and commentator responses

Comments received in the course of consultations carried out by NICE are published in the interests of openness and transparency, and to promote understanding of how recommendations are developed. The comments are published as a record of the submissions that NICE has received, and are not endorsed by NICE, its officers or advisory committees.

Name of organisation:	Lundbeck
Please indicate whether you agree or disagree with the proposal by selecting one of the following:	
Agree: <input type="checkbox"/>	Disagree: <input checked="" type="checkbox"/>
Have no comments to make: <input type="checkbox"/>	
Additional comments: (please add any additional comments you wish to make here)	
Lundbeck believe that new medicines for mental health conditions should be STA reviewed/re-reviewed for clinical & cost-effectiveness more often given the current relatively low rate of STA reviews compared with clinical guideline reviews. This will help ensure parity with physical illness treatments to secure local mandatory funding for new mental health medicines with positive STA guidance in a timely fashion.	
However, for the case of agomelatine, given the manufacturer did not make an evidence submission and the negative recommendation, it would be more efficient for NICE to re-review this medicine as part of the clinical guideline update.	

Name of organisation:	Royal College of Nursing
Please indicate whether you agree or disagree with the proposal by selecting one of the following:	
Agree: <input type="checkbox"/>	Disagree: <input type="checkbox"/>
Have no comments to make: <input checked="" type="checkbox"/>	
Additional comments: (please add any additional comments you wish to make here)	
The RCN had no comments to make regarding this review proposal at this time.	

Name of organisation:	Servier
Please indicate whether you agree or disagree with the proposal by selecting one of the following:	
Agree: <input checked="" type="checkbox"/>	Disagree: <input type="checkbox"/>
Have no comments to make: <input type="checkbox"/>	

Additional comments: (please add any additional comments you wish to make here)

Servier welcomes the opportunity to have agomelatine included in the clinical guideline.

Does Servier Laboratories intend to make a submission to the NICE Technology Appraisal programme for agomelatine at a future date? *

Yes:

No:

If so, when do Servier Laboratories anticipate this may take place? *

Paper signed off by: Meindert Boysen – Programme Director, Technology Appraisals, 5 May 2015

Contributors to this paper:

Project Manager: Andrew Kenyon